臨床泌尿器科73巻8号

2019年07月発行

特集 ハイリスク前立腺癌を深掘りする―その変遷とM0 CRPCの最新治療

〈M0 CRPC治療の現状と課題〉

背景・診断・リスク層別化と治療

著者： 杉元幹史¹

所属機関： ¹香川大学医学部泌尿器科学

ページ範囲：P.556 - P.559

文献概要

▶ポイント

・M0 CRPCは増加している．

・M0 CRPCには治療すべき患者群（高リスクM0 CRPC）がある．

・逆に必ずしも治療を急がなくてもよい患者群（低リスクM0 CRPC）もある．

参考文献

1） Smith MR, Saad F, Chowdhury S, et al : Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med 378 : 1408-1418, 2018

2） Yu EY, Miller K, Nelson J, et al : Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. J Urol 188 : 103-109, 2012

3） Traboulsi SL and Saad F : Management of nonmetastatic castration-resistant prostate cancer. Curr Opin Support Palliat Care 12 : 366-371, 2018

4） Lecouvet FE, Oprea-Lager DE, Liu Y, et al : Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer : a consensus recommendation from the EORTC Imaging Group. Lancet Oncology 19 : e534-e545, 2018

5） Smith MR, Kabbinavar F, Saad F, et al : Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23 : 2918-2925, 2005

6） Scher HI, Solo K, Valant J, et al : Prevalence of Prostate Cancer Clinical States and Mortality in the United States : Estimates Using a Dynamic Progression Model. PLoS One 10 : e0139440, 2015

7） Xie W, Regan MM, Buyse M, et al : Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. J Clin Oncol 35 : 3097-3104, 2017

8） Smith MR, Saad F, Oudard S, et al : Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer : exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31 : 3800-3806, 2013

9） Metwalli AR, Rosner IL, Cullen J, et al : Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer. Urol Oncol 32 : 761-768, 2014